Next Article in Journal
Lactiplantibacillus plantarum HY7718 Attenuates Renal Injury in an Adenine-Induced Chronic Kidney Disease Mouse Model via Inhibition of Inflammation and Apoptosis
Previous Article in Journal
HPV-Independent Cervical Cancer—A New Challenge of Modern Oncology
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 20
10.3390/ijms262010053
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Molecular Targets for Intracranial Aneurysm Treatment

by
Hunter Hutchinson
1,
Rogina Rezk
1,
Mariam Farag
1,
Abanob Hanna
1 and
Brandon Lucke-Wold
2,*
1
College of Medicine, University of Florida, Gainesville, FL 32610, USA
2
Department of Neurosurgery, University of Florida, Gainesville, FL 32608, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(20), 10053; https://doi.org/10.3390/ijms262010053
Submission received: 9 September 2025 / Revised: 9 October 2025 / Accepted: 14 October 2025 / Published: 15 October 2025
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Browse Figures
Review Reports Versions Notes

Abstract

Intracranial aneurysms (IAs) are a common cerebrovascular pathology with deadly potential. Neurointerventionalists commonly treat IAs with endovascular coiling, minimizing procedural risk at the cost of an increased recurrence rate. New therapies for reducing the rate of coiled and uncoiled IA growth and rupture would help reduce the morbidity and mortality patients experience when IAs rupture. Hemodynamic shear stress drives IA formation through molecular mechanisms, generating damage-associated molecular proteins (DAMPs), which lead to inflammation and extracellular matrix remodeling. Nuclear factor κB (NF-κB) and interleukin-6 (IL-6) maintain an inflammatory environment in IA walls, generating immune-cell chemotactic proteins, such as monocyte chemoattractant protein-1 (MCP-1) and IL-8. These molecules play a complex role in IAs, being important for IA formation and IA healing. Vascular smooth muscle cells and infiltrated immune cells secrete matrix metalloproteinases (MMPs), which initiate extracellular matrix remodeling. Tissue inhibitors of matrix metalloproteinases (TIMPs) balance this remodeling. The increased MMP to TIMP ratio is characteristic of IA progression, making these molecules important targets for IA therapies. Endothelial dysfunction generates nitric oxide and other reactive oxygen species, which exacerbate inflammation and cell death in IA walls. A better understanding of molecular mechanisms underlying IA formation, progression, and rupture will allow researchers to develop molecular IA therapies.

1. Introduction

Intracranial aneurysms (IAs) are a common cerebrovascular pathology with deadly potential. Magnetic resonance imaging (MRI) scans detect IAs in 2.3% of all patients [1]. Epidemiologically, non-modifiable risk factors for IA include a family history of cerebrovascular disease [2], female sex [2], connective tissue diseases [3], autosomal dominant polycystic kidney disease [4], and certain genetic polymorphisms [5]. Modifiable risk factors for IA include hypertension and smoking [5]. The majority of IAs are asymptomatic [6]. There is an overall 1.9% yearly risk of aneurysm rupture, leading to subarachnoid hemorrhage (SAH) [7]. Aneurysmal SAH has a high mortality rate of almost 50% and 22.8% of patients who survive aneurysmal SAH have severe neurological disabilities 5 years after IA rupture [7,8]. This risk increases with cocaine use and a family history of cerebrovascular disease [9,10]. IAs are abundant and frequently treated by neurointerventionalists because of their substantial risk.
The shared decision-making between patients and their physicians about how to treat IAs balances the mortality and morbidity of SAH with the cost and risk of surgical intervention. Initial monitoring for IAs less than 7 mm is a dual-subtraction cerebral angiogram every 6 to 12 months, with a 1-to-2-year follow-up after determination of IA stability [3,11]. Neurointerventionalists treat larger IAs with endovascular coiling or open-surgical clipping [12]. Endovascular coiling is the preferred method for IA treatment because it leads to fewer neurological deficits and shorter hospital stays [13]. However, coiled IAs still have a 10% recurrence rate within the first year and continue to recur at longer time periods [14]. Alternatively, clipped IAs have a yearly recurrence rate of only 0.7% [15]. Endovascular coiling is the most common treatment for IAs, minimizing procedural risk at the cost of increased recurrence rate.
Because of the prevalence of endovascular coiling despite its increased risk of recurrence, new therapies for reducing the rate of coiled and uncoiled IA growth and rupture are a critical area of research. An ideal therapy targets the pathophysiological components of IAs: inflammatory response, extracellular matrix (ECM) remodeling, and oxidative stress. The purpose of this narrative literature review is to overview the molecular components of IA formation and highlight target molecules for IA therapeutics in each category.

2. Inflammatory Pathways

Hemodynamic stress drives IA formation through molecular mechanisms [16]. Blood flow through cerebral arteries creates two types of stress on the endoluminal wall: tangential pressure and shear stress [16]. The initial insult leading to IA formation is high shear stress, exacerbated by hypertension, which disrupts the endothelial cell layer [16,17]. For this reason, IAs tend to occur at bifurcations or sharp curves in the cerebral vascular system [18]. Endothelial disruption by shear stress causes a phenotypic change in endothelial cells, leading to the release of inflammatory molecules and upregulation of molecules that modulate vascular tone, such as nitric oxide (NO) [19,20,21]. The tortuous, multifarious nature of cerebral vasculature creates a unique profile of hemodynamic stress, leading to endothelial release of targetable IA-forming molecules.
Hemodynamic stress draws numerous inflammatory cells to sites of IA formation [20]. Macrophage infiltration is characteristic of unruptured IAs, an attempt to repair damaged IA tissue [22]. This initiates an inflammatory cascade mediated by nuclear factor κB (NF-κB) that remodels and weakens the vascular wall [23]. Continued hydrodynamic stress causes vascular smooth muscle cells (VSMCs) to shift the phenotype from contractile to synthetic [24]. Synthetic VSMCs also initiate inflammation via NF-κB while secreting additional cytokines and matrix metalloproteinases (MMPs) that lead to ECM remodeling and IA growth [25,26]. Molecular approaches to attenuate inflammatory-cell response in the tunica media and tunica adventitia could alleviate vessel weakening and IA formation.
Toll-like receptor-4 (TLR4) activation of NF-κB mediates inflammation in IA formation [27]. Hemodynamic stress physically damages endothelial cells, which release damage-associated molecular patterns (DAMPs) that activate TLR4 signaling, initiating the synthesis of interleukin-8 IL-8, chemokine receptor ligand 1 (CXCL1), stromal-derived factor-1α (SDF-1α), and monocyte chemoattractant protein-1 (MCP-1) within endothelial cells [28,29,30,31]. Blood in human IAs contains higher concentrations of inflammatory markers than plasma from the same patients, attracting inflammatory cells to the IA site [32]. High concentrations of these molecules also exist in IA walls, leading to neutrophil infiltration [30]. Overall, NF-κB is a central regulator of inflammatory pathways triggered by vascular injury with important molecular targets for IA therapies.
A positive feedback loop maintains chronic inflammation within the aneurysm wall of IAs. NF-κB activation increases IL-6 transcription, augmenting NF-κB signaling [33]. This pro-inflammatory environment leads to the development of aneurysms and the advancement of vascular injury [33,34]. In addition, tumor necrosis factor-α (TNF-α) is a pro-inflammatory cytokine induced by tissue injury. It primarily signals through its receptor, tumor necrosis factor receptor-1 (TNFR1), leading to activation of the NF-κB pathway via a mechanism distinct from DAMP-induced TLR4 signaling [35]. It is important to note that, in addition to its pro-inflammatory effects, TNF-α also induces phenotypic modulation of VSMCs, promoting a remodeling state characterized by the upregulation of MMPs [36,37].
Balancing MCP-1 expression at distinct phases of IA formation is important for IA treatment. MCP-1 is a chemokine that functions by attracting monocytes and macrophages to areas of vascular damage, leading to further inflammation and weakening of the vessel wall in the initial stages of IAs [38]. Preventing initial MCP-1 expression on the precipice of IA formation is a futile strategy, as clinicians do not screen for IAs to detect early-stage formation [1]. Instead, attempts at molecular therapies in murine models of IAs attempt to increase the therapeutic occlusion caused by IA wall hyperplasia by endovascular coiling with MCP-1-coated coils [39]. In a murine model, MCP-1-coated coils significantly increased IA lumen ingrowth with significant macrophage, VSMC, endothelial cell, and fibroblast migration, histologically resembling successfully occluded human IAs [39,40]. MCP-1 attracts inflammatory cells that initiate IA formation and IA ingrowth, making the delivery or upregulation of MCP-1 to IAs a promising molecular therapy.
IL-8 is a neutrophil chemotactic molecule that is important in promulgating IA wall inflammation and damage. The ratio of IL-8 in the cerebrospinal fluid versus IL-8 in plasma is higher in patients with unruptured IAs [41]. However, there is insufficient evidence that IL-8 from IAs can cross the blood–brain barrier, a key limitation to interpreting the role of IL-8 in IA formation. Reminiscent of macrophage inflammation caused by MCP-1, neutrophil invasion of the aneurysm wall induced by IL-8 exacerbates inflammation and causes ECM remodeling [42]. Animal models have implicated neutrophils in IA rupture by the secretion of MMP9 [43]. Neutrophil extracellular traps (NETs) formed by extravasated neutrophils exist in ruptured IAs, interestingly less prevalent in estrogen-depleted mice [44]. The significant role of IL-8 in IA formation and rupture makes it a molecule of interest for IA therapies, whether directly or via estrogen modulation.
Given the important roles of the inflammatory markers, it is noteworthy that there are anti-inflammatory strategies targeting these pathways, such as BAY 11-7082 [45]. BAY 11-7082 is a well-characterized NF-κB inhibitor that irreversibly blocks IκBα phosphorylation, thereby preventing p65/p50 nuclear translocation and subsequent transcription of pro-inflammatory genes [45]. In addition, it suppresses the activation of activator protein-1, interferon regulator factor 3, and signal transducer and activator of transcription-1 through inhibition of extracellular signal-regulated kinase, p38, TANK-binding kinase-1, and Janus kinase-2, demonstrating a broad anti-inflammatory profile that extends beyond the established IKK/NF-κB pathway inhibition [45]. Although BAY 11-7082 is a known inhibitor of NF-κB, there have been no direct clinical studies conducted in patients with IAs, but it is a tool to track the inflammatory pathway associated with other types of aneurysms [46,47].
Direct inhibition of NF-κB signaling with small molecules may prevent IA formation and progression. Dexamethasone is a synthetic corticosteroid drug that can suppress inflammatory signaling by preventing NF-κB’s translocation to the nucleus [48]. In the context of aneurysmal inflammatory pathways, it has shown benefits in non-cerebral models, such as murine thoracic aortic aneurysm and dissection (TAAD) [49]. Daily dexamethasone treatment significantly reduced inflammatory cell inflammation and ECM degradation in a β-aminopropionitrile monofumarate-induced TAAD mouse model [49]. Systemic corticosteroids may be less effective in IA because of their small size, but a corticosteroid-delivering coil using methods like Hoh et al.’s may provide comparable results [39]. Another administration method not investigated in the literature of corticosteroids for IAs is direct intra-arterial injection at the site of an aneurysm during endovascular treatment. Overall, IA pathogenesis is rich with targetable inflammatory molecules. IA therapies are administered systemically or with coated coils. Figure 1 provides a graphical summary of molecular targets for ECM remodeling.

3. VSMC Phenotypic Shift and ECM Remodeling

The aneurysm tissue not only distends in response to stress, but it also continues to thicken as the IA progresses [16]. As it grows, the flow within the IA becomes more turbulent, decreasing the shear stress and reducing endothelial cell regulation of vascular tone while simultaneously promoting continued remodeling through increased inflammation [50]. Increased inflammation within the IA continues to increase the levels of TNF-α, which eventually degenerates VSMCs and leads to their apoptosis [51]. VSMC apoptosis and inflammation recruit more inflammatory cells with the release of molecules such as monocyte MCP-1, IL-1, and IL-8 [38,51,52]. Wall remodeling is a component of IA formation, driven by molecules targetable for IA treatment.
MMPs secreted in IA walls contribute to ECM remodeling, causing weakness, which propagates further IA distension and rupture. In response to shear stress and inflammatory molecules, VSMCs undergo a phenotypic shift from contractile to synthetic, secreting MMP-2 and MMP-9 [53]. Molecular markers for synthetic VSMCs include S100A4, CD68, and the accumulation of lipids [54]. Increased MMP concentration in IAs correlates with decreased smooth muscle actin expression and increased NF-κB and MCP-1 in a rabbit model, illustrating remodeling of IA tunica media to a less dynamic state [53]. Interestingly, VSMCs seem to be the culprit of IA remodeling in this model, as macrophage depletion did not suppress IA development [53]. ECM remodeling weakens the vessel wall’s media layers and internal elastic lamina, thus leading to the advancement of the aneurysm [55,56]. Direct inhibition of MMP-2 and MMP-9 with a selective inhibitor did not show improvements in the aneurysm rupture rate in a murine model, implying MMPs do not act alone in IA rupture pathogenesis [57]. Based on this evidence, MMPs play a greater role in early IA formation but may be less viable molecular targets at a clinically relevant stage of IA development [55,57].
Endogenous tissue inhibitors of metalloproteinases (TIMPs) may protect from IA ECM remodeling by preventing the action of MMP-2 and MMP-9. VSMCs release TIMP-1 and TIMP-2 in the tunica media, within 15 days of IA induction in a rat model [58]. However, as the disease progresses, MMP expression outpaces TIMP expression [58]. The loss of parallel TIMP activity may be the cause of continued IA growth and rupture. TIMP knockout rats had significantly less ß-actin, marking less contractile VSMCs to respond to vascular stress, compared to wild-type mice [58]. Although IA incidence did not change in TIMP knockout mice, IA progression significantly increased [58,59]. Delivery of mRNA to increase the TIMP-1 ratio improves ECM integrity in animal models of abdominal aortic aneurysm; however, no literature exists on TIMP supplementation in IAs [60]. The TIMP/MMP ratio is a defining feature of IA progression, causing the delivery of molecules that increase the TIMP levels, a valuable IA therapeutic target.
Transforming growth factor-ß (TGF-ß) is another ECM-remodeling molecule implicated in IA progression. Human saccular IAs express significantly increased TGF-ß-R3 compared to healthy tissue, making TGF-ß a target for molecular IA therapy [60]. Specific literature on TGF-ß’s mechanistic role in IAs is unavailable. Further research should explore the role of TGF ligands and receptors with local inhibitors or knockout animal models to establish TGF-ß’s role in IA therapeutics. Delivery of therapies targeting ECM remodeling via coated coils would be ideal, as the systemic effects of reduced ECM remodeling activity could be detrimental to wound healing [61]. Another challenge will be delivery across the endothelial layer into the IA tunica media and adventitia, where ECM remodeling is taking place. Overall, intervening in IA progression via ECM remodeling is promising, but underexplored. Figure 2 provides a graphical summary of molecular targets for ECM remodeling.

4. Endothelial Dysfunction, Oxidative Stress, and Cell Death

Damage from wall shear stress and local inflammation disrupts endothelial nitric oxide synthase (eNOS), the primary regulator of vascular homeostasis, leading to IA formation [62]. Nitric oxide (NO) is a potent vasodilator and reactive oxygen species (ROS) generated by nitric oxide synthase (NOS) enzymes [63]. Increased stress on the lumen wall typically upregulates eNOS activity, but hemodynamic stress is low in IAs, which may lead to VSMC vasoconstriction and pro-inflammatory activity [64]. Polymorphisms in the eNOS gene rs1799983 change the risk of developing IAs, meaning eNOS may be an actionable target for IA therapy [65]. However, NOS inhibition with the small molecule L-arginine derivative, N(G)-nitro-L-arginine-methyl ester, reduces IA formation in a rabbit-induced IA model, counter to the logic that eNOS downregulation contributes to IA formation [66]. Endothelial dysfunction is a prelude to IA formation, facilitated by loss of eNOS, but other NOS species may be of greater importance in IA formation [67,68].
NO plays a greater role as a damaging, inflammatory ROS than a protective vasodilator in IA formation. Pathologically high NO levels, greater than VSMCs, can occur in IAs because their pro-inflammatory milieu induces the intrinsic NO synthase (iNOS) of infiltrating immune cells to form NO as a ROS for host defense [69]. Extremely elevated levels of NO downregulate eNOS via negative feedback, and NO works with other ROS from inflammatory cells to disrupt endothelial permeability and recruit more inflammatory cells via TNF-α and IL-1 release [69,70,71]. Non-selective NOS inhibitors reduce IA formation in animal models because of NO’s inflammatory role [66]. Interestingly, iNOS knockout mice have no increased rate of aneurysm formation, but when aneurysms do form, they have a greater size [72]. Endothelial dysfunction via reduced eNOS may play a role in IA formation, but NO’s role is primarily inflammatory once an IA forms, making iNOS and other generators of ROS more important molecular targets for IA therapy than eNOS.
One of the mechanisms that can result in damage in IA formation is through the production of ROS-generated inflammatory pathways. Aneurysmal blood flow is turbulent, specifically at points of bifurcation [73]. Turbulent flow increases reactive oxygen species production, which contributes to vascular wall injury and increases endothelial damage [38,72,74]. Increased ROS can oxidize lipids, damage mitochondrial DNA, and inactivate proteases [75]. Increased inflammation and impaired nitric oxide bioavailability result in VSMC apoptosis and disruption of the tunica media [76]. Additionally, ROS can directly activate transcription factors such as NF-κB, which further increase inflammatory markers [77,78]. They also disrupt NO synthesis, leading to endothelial dysfunction. Because ROS are key to IA formation, molecular treatments for IAs could target ROS or the molecules.
The NADPH pathway is key to ROS generation, but no investigations of NADPH in IAs exist in the literature [79]. In response to mechanical stress, endothelial and smooth muscle dysfunctions lead to increased NADPH oxidase activity, specifically NADPH oxidase (NOX) isoforms, including NOX1 and NOX2, in aneurysmal walls [80]. Specific NOX inhibitors can dampen ROS production and inflammation [80]. NADPH oxidase inhibitors significantly reduce abdominal aortic aneurysm formation [80]. Isoform-specific inhibitors for NOX1 and NOX2 are promising therapeutic agents in reducing the burden of oxidative stress in the central nervous system [80,81,82]. Further investigation of the NADPH pathway and NOX enzymes in IAs could provide another molecular target for IA therapy.
Resveratrol is an antioxidant polyphenol that reduces IA formation and rupture rates in mouse models [83,84]. Resveratrol induces epigenetic upregulation of antioxidative genes, superoxide dismutase, catalase, and FoxOs [85]. In a murine, hypertension-induced IA model, an RA-containing diet significantly inhibited the IA size and wall thickness compared to untreated mice [84]. Investigation of aneurysm walls revealed significantly lower macrophage infiltration, and Western blots measured lower MMP-2, MMP-9, and NF-κB in resveratrol-treated groups [84]. A similar intervention with dietary resveratrol in an elastase injection model of IA revealed no significant difference in IA formation, but a decrease in IA rupture rate [83]. By scavenging ROS to reduce oxidative stress, resveratrol may reduce the inflammation characteristic of IA formation and rupture [83,84].
RNA gene therapies could suppress NOX2/NOX4 signaling involved in oxidative damage or degrade pro-apoptotic inflammatory cytokines. Differential expression of microRNAs (miRNAs) is related to the ECM NOX function in aneurysmal tissue, such as miR-21, which can serve as a specific target for aneurysmal miRNAs [86,87]. An additional study recently developed neutrophil-mimetic nanoparticles coated with metal–organic frameworks to deliver siRNA targeting NOX4, with the goal of significantly reducing the ROS and ischemic injury in mouse models, highlighting the promise of targeted RNA therapies in vascular oxidative stress [88]. Overall, for molecular scientists to develop IA treatments targeting endothelial dysfunction and ROS, they will need to perform more mechanistic research.

5. Future Directions

More research to determine the initiating event of IA formation can help develop preventative, instead of remedial, therapies. Patients with IAs are usually asymptomatic, which makes studying IA initiation difficult [89]. Potential IA biomarkers discovered in proteomics studies are promising, but larger-scale investigations must confirm their efficacy [90,91]. IA biomarker candidates, such as MMP-9, are non-specific, but new artificial intelligence tools could discover more complex patterns in biomarker arrays for IA risk prediction, a growing trend seen in other fields, such as oncology [92]. Less invasive screening methods able to predict patients at risk of IAs will allow for systemic IA deployment. Developing biomarker screening tools to detect patients at risk of IA formation will be key to creating efficacious molecular IA therapies [93].
Circulating miRNAs are another area of promising IA research. A litany of miRNA species are reported to increase in the peripheral blood of patients with IAs compared to healthy controls [94,95,96,97]. The impetus to test for these miRNAs comes from genome-wide association studies reporting risk loci for IA formation [98,99]. These circulating miRNAs likely reflect the epigenetic shifts and molecular mechanisms of IA formation, but further investigation with larger clinical trials is needed to determine the sensitivity and specificity of each miRNA [100].
Unfortunately, many of the inflammatory molecules and cells implicated in IA progression are nonspecific and fundamental to survival, making continuous depletion with small molecules, interfering with RNA, or gene knockout difficult. One solution to this problem is spatiotemporally controlled mutant mice using the Cre-loxP system [101]. In brief, mice bred with loxP sites, flanking genes encoding a protein of interest in a specific tissue, have genes selectively inducible or inhibited by tamoxifen administration-activated Cre recombinase [101]. Halting tamoxifen administration reverses the effects of Cre [101]. This allows mice to be their own control in induced IA models, with growth measured with and without gene knockout by tamoxifen. The importance of different chemotactic cytokines, MMPs, and TIMPs at various stages of IA development is comparable using this method. Cre-loxP models would provide more validity in IA research, as most investigations focus on less-specific therapeutic molecules instead of a mechanistic explanation of IA formation.
Intravascular administration of small molecules or gene therapies targeting molecules implicated in induction, progression, and rupture is the ideal therapy for IAs [46]. Current guidelines for unruptured IA treatment recommend no specific systemic pharmacologic therapies [3]. Some retrospective observational studies suggest that patients taking anti-inflammatory medications such as aspirin reduce IA progression [102,103]. Systemic therapies targeting IL-6, TNF-α, and neutrophils are applied in other pathologies with inflammatory etiologies with great success, but leave patients immunocompromised [104,105,106]. Future randomized controlled trials of anti-inflammatory therapies targeting molecules implicated in IA progression must confirm that anti-inflammatory molecules are beneficial for patients with unruptured IAs, especially with their possible adverse effects. MMPs or TIMPs are not therapeutic targets used in current medical practice, providing less precedence for their use as a systemic therapy. As MMPs and TIMPs are ubiquitous, systemic therapies will likely have off-target effects, such as fibrosis [107]. Drugs targeting inflammation, MMPs, or ROS to reduce IA formation could be administered intra-arterially to reduce off-target effects of intravascular therapy, as calcium-channel blockers are administered for cerebral vasospasm in subarachnoid hemorrhage [108,109]. Overall, intravascular therapies for IAs targeting molecules implicated in IA formation, growth, and rupture are promising but will require diligent investigation in clinical trials to optimize dosage, aim at specific targets, and reduce adverse effects.
Designing systemic molecular IA therapies is difficult because IAs are a small compartment to target, even with direct intra-arterial administration. Molecular therapies should focus on deployment during endovascular procedures because coiling or stenting is the standard of care for IAs [110]. Most preclinical studies use direct, one-time delivery of therapy to IAs, which have a short duration of action. Gene therapies targeting molecules implicated in IA formation have the potential to provide a more sustainable therapy that can also penetrate deeper into IA layers [111]. More researchers should explore coil-coating as a delivery method, as this is the most promising application for implementing molecular IA therapies into the current IA standard of care [39,112]. Overall, future directions of molecular IA research include investigation of IA formation for screening biomarker development; more specific, temporal gene knockout studies to compare the importance of different molecules in IA progression; and exploration of pertinent routes of administration.

6. Conclusions

IAs are common and have a high mortality rate when they rupture [113]. Inflammation is a key mediator of IA formation. Chemotactic proteins such as MCP-1 and IL-8 facilitate immune cell infiltration into the endovascular wall, exacerbating an inflammatory cascade initiated by hemodynamic shear stress. The overall result is ECM remodeling to create a vascular wall unable to respond appropriately to stress. Temporally increasing the MMP-to-TIMP ratio is an important temporal pattern that molecular therapies could modulate. Another vital component of IA pathogenesis is endothelial dysfunction of reduced eNOS and increased synthesis of NO by iNOS, leading to vasoconstriction and formation of reactive oxygen species, further increasing inflammation. Future investigation into molecules associated with IA initiation, progression, and rupture aids the creation of tools to screen patients at risk of IA and molecular adjuvant therapies deployed during endovascular IA treatment.

Author Contributions

Conceptualization, B.L.-W.; writing—original draft preparation, H.H., R.R., M.F., and A.H.; writing—review and editing, H.H.; graphical abstract and figure creation, H.H.; supervision, B.L.-W. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
IAIntracranial Aneurysm
MRIMagnetic Resonance Imaging
SAHSubarachnoid Hemorrhage
ECMExtracellular Matrix
NONitric Oxide
NF-κBNuclear Factor κB
VSMCVascular Smooth Muscle Cell
MMPMatrix Metalloproteinase
TLR4Toll-like receptor-4
DAMPDamage-associated molecular patterns
ILInterleukin
CXCLChemokine receptor ligand
SDF-1αStromal-Cell-Derived Factor-1α
MCP-1Monocyte Chemoattractant Protein-1
TNF-αTumor Necrosis Factor-α
TNFR1Tumor Necrosis Factor Receptor 1
NETNeutrophil Extracellular Trap
TAADThoracic Aortic Aneurysm and Dissection
TIMPTissue Inhibitor of Metalloproteinases
TGF-ßTransforming Growth Factor-ß
eNOSEndothelial Nitric Oxide Synthase
ROSReactive Oxygen Species
iNOSIntrinsic Nitric Oxide Synthase
NOXNADPH Oxidase

References

  1. Bos, D.; Poels, M.M.F.; Adams, H.H.H.; Akoudad, S.; Cremers, L.G.M.; Zonneveld, H.I.; Hoogendam, Y.Y.; Verhaaren, B.F.J.; Verlinden, V.J.A.; Verbruggen, J.G.J.; et al. Prevalence, Clinical Management, and Natural Course of Incidental Findings on Brain MR Images: The Population-Based Rotterdam Scan Study. Radiology 2016, 281, 507–515. [Google Scholar] [CrossRef]
  2. Vlak, M.H.; Algra, A.; Brandenburg, R.; Rinkel, G.J. Prevalence of Unruptured Intracranial Aneurysms, with Emphasis on Sex, Age, Comorbidity, Country, and Time Period: A Systematic Review and Meta-Analysis. Lancet Neurol. 2011, 10, 626–636. [Google Scholar] [CrossRef]
  3. Thompson, B.G.; Brown, R.D.; Amin-Hanjani, S.; Broderick, J.P.; Cockroft, K.M.; Connolly, E.S.; Duckwiler, G.R.; Harris, C.C.; Howard, V.J.; Johnston, S.C.; et al. Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms. Stroke 2015, 46, 2368–2400. [Google Scholar] [CrossRef]
  4. Nguyen, B.A.; Halpin, B.; Olson, V.; Putzler, D.; Ghoche, M.; Pachón-Londoño, M.J.; Turcotte, E.L.; Maroufi, S.F.; Segovia, D.; Patra, D.P.; et al. Risk Factors for Unruptured Intracranial Aneurysms in Asymptomatic Patients with Autosomal Dominant Polycystic Kidney Disease: Who Needs Screening? A Systematic Review and Meta-Analysis. J. Neurosurg. 2025, 143, 220–231. [Google Scholar] [CrossRef]
  5. Alg, V.S.; Sofat, R.; Houlden, H.; Werring, D.J. Genetic Risk Factors for Intracranial Aneurysms: A Meta-Analysis in More than 116,000 Individuals. Neurology 2013, 80, 2154–2165. [Google Scholar] [CrossRef]
  6. Lawton, M.T.; Vates, G.E. Subarachnoid Hemorrhage. N. Engl. J. Med. 2017, 377, 257–266. [Google Scholar] [CrossRef] [PubMed]
  7. Rinkel, G.J.; Djibuti, M.; Algra, A.; van Gijn, J. Prevalence and Risk of Rupture of Intracranial Aneurysms: A Systematic Review. Stroke 1998, 29, 251–256. [Google Scholar] [CrossRef] [PubMed]
  8. Lee, H.S.; Sohn, M.K.; Lee, J.; Kim, D.Y.; Shin, Y.-I.; Oh, G.-J.; Lee, Y.-S.; Joo, M.C.; Lee, S.Y.; Song, M.-K.; et al. Five-Year Functional Outcomes Among Patients Surviving Aneurysmal Subarachnoid Hemorrhage. JAMA Netw. Open 2025, 8, e251678. [Google Scholar] [CrossRef]
  9. van Rooij, W.J.; Sluzewski, M.; Beute, G.N. Endovascular Treatment of Posterior Cerebral Artery Aneurysms. AJNR Am. J. Neuroradiol. 2006, 27, 300–305. [Google Scholar] [PubMed]
  10. Florez-Perdomo, W.A.; Reyes Bello, J.S.; García-Ballestas, E.; Moscote-Salazar, L.R.; Barthélemy, E.J.; Janjua, T.; Maurya, V.P.; Agrawal, A. Aneurysmal Subarachnoid Hemorrhage and Cocaine Consumption: A Systematic Review and Metanalysis. World Neurosurg. 2024, 184, 241–252.e2. [Google Scholar] [CrossRef]
  11. Expert Panel on Neurological Imaging; Ledbetter, L.N.; Burns, J.; Shih, R.Y.; Ajam, A.A.; Brown, M.D.; Chakraborty, S.; Davis, M.A.; Ducruet, A.F.; Hunt, C.H.; et al. ACR Appropriateness Criteria® Cerebrovascular Diseases-Aneurysm, Vascular Malformation, and Subarachnoid Hemorrhage. J. Am. Coll. Radiol. 2021, 18, S283–S304. [Google Scholar] [CrossRef]
  12. Zhao, J.; Lin, H.; Summers, R.; Yang, M.; Cousins, B.G.; Tsui, J. Current Treatment Strategies for Intracranial Aneurysms: An Overview. Angiology 2018, 69, 17–30. [Google Scholar] [CrossRef]
  13. Darsaut, T.E.; Findlay, J.M.; Bojanowski, M.W.; Chalaala, C.; Iancu, D.; Roy, D.; Weill, A.; Boisseau, W.; Diouf, A.; Magro, E.; et al. A Pragmatic Randomized Trial Comparing Surgical Clipping and Endovascular Treatment of Unruptured Intracranial Aneurysms. AJNR Am. J. Neuroradiol. 2023, 44, 634–640. [Google Scholar] [CrossRef] [PubMed]
  14. Tian, Z.; Liu, J.; Zhang, Y.; Zhang, Y.; Zhang, X.; Zhang, H.; Yang, M.; Yang, X.; Wang, K. Risk Factors of Angiographic Recurrence After Endovascular Coil Embolization of Intracranial Saccular Aneurysms: A Retrospective Study Using a Multicenter Database. Front. Neurol. 2020, 11, 1026. [Google Scholar] [CrossRef] [PubMed]
  15. Marbacher, S.; Grüter, B.E.; Wanderer, S.; Andereggen, L.; Cattaneo, M.; Trost, P.; Gruber, P.; Diepers, M.; Remonda, L.; Steiger, H.-J. Risk of Intracranial Aneurysm Recurrence after Microsurgical Clipping Based on 3D Digital Subtraction Angiography. J. Neurosurg. 2023, 138, 717–723. [Google Scholar] [CrossRef]
  16. Turjman, A.S.; Turjman, F.; Edelman, E.R. Role of Fluid Dynamics and Inflammation in Intracranial Aneurysm Formation. Circulation 2014, 129, 373–382. [Google Scholar] [CrossRef]
  17. Zimny, M.; Kawlewska, E.; Hebda, A.; Wolański, W.; Ładziński, P.; Kaspera, W. Wall Shear Stress Gradient Is Independently Associated with Middle Cerebral Artery Aneurysm Development: A Case-Control CFD Patient-Specific Study Based on 77 Patients. BMC Neurol. 2021, 21, 281. [Google Scholar] [CrossRef]
  18. Brisman, J.L.; Song, J.K.; Newell, D.W. Cerebral Aneurysms. N. Engl. J. Med. 2006, 355, 928–939. [Google Scholar] [CrossRef] [PubMed]
  19. Aird, W.C. Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms. Circ. Res. 2007, 100, 158–173. [Google Scholar] [CrossRef]
  20. Chalouhi, N.; Ali, M.S.; Jabbour, P.M.; Tjoumakaris, S.I.; Gonzalez, L.F.; Rosenwasser, R.H.; Koch, W.J.; Dumont, A.S. Biology of Intracranial Aneurysms: Role of Inflammation. J. Cereb. Blood Flow Metab. 2012, 32, 1659–1676. [Google Scholar] [CrossRef]
  21. Arnal, J.F.; Dinh-Xuan, A.T.; Pueyo, M.; Darblade, B.; Rami, J. Endothelium-Derived Nitric Oxide and Vascular Physiology and Pathology. Cell. Mol. Life Sci. 1999, 55, 1078–1087. [Google Scholar] [CrossRef]
  22. Frösen, J.; Piippo, A.; Paetau, A.; Kangasniemi, M.; Niemelä, M.; Hernesniemi, J.; Jääskeläinen, J. Remodeling of Saccular Cerebral Artery Aneurysm Wall Is Associated with Rupture: Histological Analysis of 24 Unruptured and 42 Ruptured Cases. Stroke 2004, 35, 2287–2293. [Google Scholar] [CrossRef]
  23. Page-McCaw, A.; Ewald, A.J.; Werb, Z. Matrix Metalloproteinases and the Regulation of Tissue Remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8, 221–233. [Google Scholar] [CrossRef] [PubMed]
  24. Orr, A.W.; Hastings, N.E.; Blackman, B.R.; Wamhoff, B.R. Complex Regulation and Function of the Inflammatory Smooth Muscle Cell Phenotype in Atherosclerosis. J. Vasc. Res. 2010, 47, 168–180. [Google Scholar] [CrossRef] [PubMed]
  25. Kolega, J.; Gao, L.; Mandelbaum, M.; Mocco, J.; Siddiqui, A.H.; Natarajan, S.K.; Meng, H. Cellular and Molecular Responses of the Basilar Terminus to Hemodynamics during Intracranial Aneurysm Initiation in a Rabbit Model. J. Vasc. Res. 2011, 48, 429–442. [Google Scholar] [CrossRef]
  26. Khan, D.; Cornelius, J.F.; Muhammad, S. The Role of NF-κB in Intracranial Aneurysm Pathogenesis: A Systematic Review. Int. J. Mol. Sci. 2023, 24, 14218. [Google Scholar] [CrossRef]
  27. Aoki, T.; Nishimura, M.; Ishibashi, R.; Kataoka, H.; Takagi, Y.; Hashimoto, N. Toll-like Receptor 4 Expression during Cerebral Aneurysm Formation. Laboratory Investigation. J. Neurosurg. 2010, 113, 851–858, Erratum in J. Neurosurg. 2010, 119, 825–827. [Google Scholar] [CrossRef] [PubMed]
  28. Zhu, H.; Hao, Z.; Xing, Z.; Tan, J.; Zhao, Y.; Li, M. Impinging Flow Induces Expression of Monocyte Chemoattractant Protein-1 in Endothelial Cells Through Activation of the c-Jun N-Terminal Kinase/c-Jun/P38/c-Fos Pathway. World Neurosurg. 2022, 164, e681–e693. [Google Scholar] [CrossRef]
  29. Hoh, B.L.; Hosaka, K.; Downes, D.P.; Nowicki, K.W.; Wilmer, E.N.; Velat, G.J.; Scott, E.W. Stromal Cell-Derived Factor-1 Promoted Angiogenesis and Inflammatory Cell Infiltration in Aneurysm Walls. J. Neurosurg. 2014, 120, 73–86. [Google Scholar] [CrossRef]
  30. Nowicki, K.W.; Hosaka, K.; He, Y.; McFetridge, P.S.; Scott, E.W.; Hoh, B.L. Novel High-Throughput in Vitro Model for Identifying Hemodynamic-Induced Inflammatory Mediators of Cerebral Aneurysm Formation. Hypertension 2014, 64, 1306–1313. [Google Scholar] [CrossRef]
  31. Mitsui, K.; Ikedo, T.; Kamio, Y.; Furukawa, H.; Lawton, M.T.; Hashimoto, T. TLR4 (Toll-Like Receptor 4) Mediates the Development of Intracranial Aneurysm Rupture. Hypertension 2020, 75, 468–476. [Google Scholar] [CrossRef]
  32. Chalouhi, N.; Points, L.; Pierce, G.L.; Ballas, Z.; Jabbour, P.; Hasan, D. Localized Increase of Chemokines in the Lumen of Human Cerebral Aneurysms. Stroke 2013, 44, 2594–2597. [Google Scholar] [CrossRef]
  33. Duan, J.; Zhao, Q.; He, Z.; Tang, S.; Duan, J.; Xing, W. Current Understanding of Macrophages in Intracranial Aneurysm: Relevant Etiological Manifestations, Signaling Modulation and Therapeutic Strategies. Front. Immunol. 2023, 14, 1320098. [Google Scholar] [CrossRef] [PubMed]
  34. Wang, J.; Wei, L.; Lu, H.; Zhu, Y. Roles of Inflammation in the Natural History of Intracranial Saccular Aneurysms. J. Neurol. Sci. 2021, 424, 117294. [Google Scholar] [CrossRef]
  35. Aoki, T.; Fukuda, M.; Nishimura, M.; Nozaki, K.; Narumiya, S. Critical Role of TNF-Alpha-TNFR1 Signaling in Intracranial Aneurysm Formation. Acta Neuropathol. Commun. 2014, 2, 34. [Google Scholar] [CrossRef] [PubMed]
  36. Starke, R.M.; Raper, D.M.S.; Ding, D.; Chalouhi, N.; Owens, G.K.; Hasan, D.M.; Medel, R.; Dumont, A.S. Tumor Necrosis Factor-α Modulates Cerebral Aneurysm Formation and Rupture. Transl. Stroke Res. 2014, 5, 269–277. [Google Scholar] [CrossRef]
  37. Ali, M.S.; Starke, R.M.; Jabbour, P.M.; Tjoumakaris, S.I.; Gonzalez, L.F.; Rosenwasser, R.H.; Owens, G.K.; Koch, W.J.; Greig, N.H.; Dumont, A.S. TNF-α Induces Phenotypic Modulation in Cerebral Vascular Smooth Muscle Cells: Implications for Cerebral Aneurysm Pathology. J. Cereb. Blood Flow Metab. 2013, 33, 1564–1573. [Google Scholar] [CrossRef] [PubMed]
  38. Aoki, T.; Kataoka, H.; Ishibashi, R.; Nozaki, K.; Egashira, K.; Hashimoto, N. Impact of Monocyte Chemoattractant Protein-1 Deficiency on Cerebral Aneurysm Formation. Stroke 2009, 40, 942–951. [Google Scholar] [CrossRef]
  39. Hoh, B.L.; Hosaka, K.; Downes, D.P.; Nowicki, K.W.; Fernandez, C.E.; Batich, C.D.; Scott, E.W. Monocyte Chemotactic Protein-1 Promotes Inflammatory Vascular Repair of Murine Carotid Aneurysms via a Macrophage Inflammatory Protein-1α and Macrophage Inflammatory Protein-2-Dependent Pathway. Circulation 2011, 124, 2243–2252. [Google Scholar] [CrossRef]
  40. Bavinzski, G.; Talazoglu, V.; Killer, M.; Richling, B.; Gruber, A.; Gross, C.E.; Plenk, H. Gross and Microscopic Histopathological Findings in Aneurysms of the Human Brain Treated with Guglielmi Detachable Coils. J. Neurosurg. 1999, 91, 284–293. [Google Scholar] [CrossRef]
  41. Kamińska, J.; Lyson, T.; Chrzanowski, R.; Sawicki, K.; Milewska, A.J.; Tylicka, M.; Zińczuk, J.; Matowicka-Karna, J.; Dymicka-Piekarska, V.; Mariak, Z.; et al. Ratio of IL-8 in CSF versus Serum Is Elevated in Patients with Unruptured Brain Aneurysm. J. Clin. Med. 2020, 9, 1761. [Google Scholar] [CrossRef]
  42. Houard, X.; Touat, Z.; Ollivier, V.; Louedec, L.; Philippe, M.; Sebbag, U.; Meilhac, O.; Rossignol, P.; Michel, J.-B. Mediators of Neutrophil Recruitment in Human Abdominal Aortic Aneurysms. Cardiovasc. Res. 2009, 82, 532–541. [Google Scholar] [CrossRef]
  43. Kushamae, M.; Miyata, H.; Shirai, M.; Shimizu, K.; Oka, M.; Koseki, H.; Abekura, Y.; Ono, I.; Nozaki, K.; Mizutani, T.; et al. Involvement of Neutrophils in Machineries Underlying the Rupture of Intracranial Aneurysms in Rats. Sci. Rep. 2020, 10, 20004. [Google Scholar] [CrossRef] [PubMed]
  44. Patel, D.; Dodd, W.S.; Lucke-Wold, B.; Chowdhury, M.A.B.; Hosaka, K.; Hoh, B.L. Neutrophils: Novel Contributors to Estrogen-Dependent Intracranial Aneurysm Rupture Via Neutrophil Extracellular Traps. J. Am. Heart Assoc. 2023, 12, e029917. [Google Scholar] [CrossRef] [PubMed]
  45. Lee, J.; Rhee, M.H.; Kim, E.; Cho, J.Y. BAY 11-7082 Is a Broad-Spectrum Inhibitor with Anti-Inflammatory Activity against Multiple Targets. Mediat. Inflamm. 2012, 2012, 416036. [Google Scholar] [CrossRef] [PubMed]
  46. Crane, A.; Shanahan, R.M.; Hudson, J.S.; Nowicki, K.W.; Gersey, Z.C.; Agarwal, P.; Jacobs, R.C.; Lang, M.J.; Gross, B. Pharmaceutical Modulation of Intracranial Aneurysm Development and Rupture. J. Clin. Med. 2024, 13, 3324. [Google Scholar] [CrossRef]
  47. Muhammad, S.; Chaudhry, S.R.; Dobreva, G.; Lawton, M.T.; Niemelä, M.; Hänggi, D. Vascular Macrophages as Therapeutic Targets to Treat Intracranial Aneurysms. Front. Immunol. 2021, 12, 630381. [Google Scholar] [CrossRef]
  48. De Bosscher, K.; Schmitz, M.L.; Vanden Berghe, W.; Plaisance, S.; Fiers, W.; Haegeman, G. Glucocorticoid-Mediated Repression of Nuclear Factor-kappaB-Dependent Transcription Involves Direct Interference with Transactivation. Proc. Natl. Acad. Sci. USA 1997, 94, 13504–13509. [Google Scholar] [CrossRef]
  49. Wang, X.; Zhang, X.; Qiu, T.; Yang, Y.; Li, Q.; Zhang, X. Dexamethasone Reduces the Formation of Thoracic Aortic Aneurysm and Dissection in a Murine Model. Exp. Cell Res. 2021, 405, 112703. [Google Scholar] [CrossRef]
  50. Meng, H.; Tutino, V.M.; Xiang, J.; Siddiqui, A. High WSS or Low WSS? Complex Interactions of Hemodynamics with Intracranial Aneurysm Initiation, Growth, and Rupture: Toward a Unifying Hypothesis. AJNR Am. J. Neuroradiol. 2014, 35, 1254–1262. [Google Scholar] [CrossRef]
  51. Jayaraman, T.; Paget, A.; Shin, Y.S.; Li, X.; Mayer, J.; Chaudhry, H.; Niimi, Y.; Silane, M.; Berenstein, A. TNF-Alpha-Mediated Inflammation in Cerebral Aneurysms: A Potential Link to Growth and Rupture. Vasc. Health Risk Manag. 2008, 4, 805–817. [Google Scholar] [CrossRef]
  52. Jayaraman, T.; Berenstein, V.; Li, X.; Mayer, J.; Silane, M.; Shin, Y.S.; Niimi, Y.; Kiliç, T.; Gunel, M.; Berenstein, A. Tumor Necrosis Factor Alpha Is a Key Modulator of Inflammation in Cerebral Aneurysms. Neurosurgery 2005, 57, 558–564, discussion 558–564. [Google Scholar] [CrossRef]
  53. Mandelbaum, M.; Kolega, J.; Dolan, J.M.; Siddiqui, A.H.; Meng, H. A Critical Role for Proinflammatory Behavior of Smooth Muscle Cells in Hemodynamic Initiation of Intracranial Aneurysm. PLoS ONE 2013, 8, e74357. [Google Scholar] [CrossRef]
  54. Nakajima, N.; Nagahiro, S.; Sano, T.; Satomi, J.; Satoh, K. Phenotypic Modulation of Smooth Muscle Cells in Human Cerebral Aneurysmal Walls. Acta Neuropathol. 2000, 100, 475–480. [Google Scholar] [CrossRef]
  55. Aoki, T.; Kataoka, H.; Morimoto, M.; Nozaki, K.; Hashimoto, N. Macrophage-Derived Matrix Metalloproteinase-2 and -9 Promote the Progression of Cerebral Aneurysms in Rats. Stroke 2007, 38, 162–169. [Google Scholar] [CrossRef]
  56. Bruno, G.; Todor, R.; Lewis, I.; Chyatte, D. Vascular Extracellular Matrix Remodeling in Cerebral Aneurysms. J. Neurosurg. 1998, 89, 431–440. [Google Scholar] [CrossRef]
  57. Makino, H.; Tada, Y.; Wada, K.; Liang, E.I.; Chang, M.; Mobashery, S.; Kanematsu, Y.; Kurihara, C.; Palova, E.; Kanematsu, M.; et al. Pharmacological Stabilization of Intracranial Aneurysms in Mice: A Feasibility Study. Stroke 2012, 43, 2450–2456. [Google Scholar] [CrossRef] [PubMed]
  58. Aoki, T.; Kataoka, H.; Moriwaki, T.; Nozaki, K.; Hashimoto, N. Role of TIMP-1 and TIMP-2 in the Progression of Cerebral Aneurysms. Stroke 2007, 38, 2337–2345. [Google Scholar] [CrossRef]
  59. Fischer, M.; Dietmann, A.; Beer, R.; Broessner, G.; Helbok, R.; Pfausler, B.; Schmutzhard, E.; Lackner, P. Differential Regulation of Matrix-Metalloproteinases and Their Tissue Inhibitors in Patients with Aneurysmal Subarachnoid Hemorrhage. PLoS ONE 2013, 8, e59952. [Google Scholar] [CrossRef] [PubMed]
  60. Golombek, S.; Doll, I.; Kaufmann, L.; Lescan, M.; Schlensak, C.; Avci-Adali, M. A Novel Strategy for the Treatment of Aneurysms: Inhibition of MMP-9 Activity through the Delivery of TIMP-1 Encoding Synthetic mRNA into Arteries. Int. J. Mol. Sci. 2024, 25, 6599. [Google Scholar] [CrossRef] [PubMed]
  61. Huang, J.; Heng, S.; Zhang, W.; Liu, Y.; Xia, T.; Ji, C.; Zhang, L.-J. Dermal Extracellular Matrix Molecules in Skin Development, Homeostasis, Wound Regeneration and Diseases. Semin. Cell Dev. Biol. 2022, 128, 137–144. [Google Scholar] [CrossRef]
  62. Staarmann, B.; Smith, M.; Prestigiacomo, C.J. Shear Stress and Aneurysms: A Review. Neurosurg. Focus 2019, 47, E2. [Google Scholar] [CrossRef] [PubMed]
  63. Moncada, S.; Higgs, E.A. Nitric Oxide and the Vascular Endothelium. In Handbook of Experimental Pharmacology; Springer: Berlin/Heidelberg, Germany, 2006; pp. 213–254. [Google Scholar] [CrossRef]
  64. Hwang, J.; Ing, M.H.; Salazar, A.; Lassègue, B.; Griendling, K.; Navab, M.; Sevanian, A.; Hsiai, T.K. Pulsatile versus Oscillatory Shear Stress Regulates NADPH Oxidase Subunit Expression: Implication for Native LDL Oxidation. Circ. Res. 2003, 93, 1225–1232. [Google Scholar] [CrossRef] [PubMed]
  65. Usategui-Martín, R.; Jiménez-Arribas, P.; Sakas-Gandullo, C.; González-Sarmiento, R.; Rodríguez-Arias, C.A. Endothelial Nitric Oxide Synthase Rs1799983 Gene Polymorphism Is Associated with the Risk of Developing Intracranial Aneurysm. Acta Neurochir. 2023, 165, 1261–1267. [Google Scholar] [CrossRef]
  66. Liaw, N.; Fox, J.M.D.; Siddiqui, A.H.; Meng, H.; Kolega, J. Endothelial Nitric Oxide Synthase and Superoxide Mediate Hemodynamic Initiation of Intracranial Aneurysms. PLoS ONE 2014, 9, e101721. [Google Scholar] [CrossRef]
  67. Daiber, A.; Xia, N.; Steven, S.; Oelze, M.; Hanf, A.; Kröller-Schön, S.; Münzel, T.; Li, H. New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease. Int. J. Mol. Sci. 2019, 20, 187. [Google Scholar] [CrossRef] [PubMed]
  68. Sheinberg, D.L.; McCarthy, D.J.; Elwardany, O.; Bryant, J.-P.; Luther, E.; Chen, S.H.; Thompson, J.W.; Starke, R.M. Endothelial Dysfunction in Cerebral Aneurysms. Neurosurg. Focus 2019, 47, E3. [Google Scholar] [CrossRef]
  69. Fukuda, S.; Hashimoto, N.; Naritomi, H.; Nagata, I.; Nozaki, K.; Kondo, S.; Kurino, M.; Kikuchi, H. Prevention of Rat Cerebral Aneurysm Formation by Inhibition of Nitric Oxide Synthase. Circulation 2000, 101, 2532–2538. [Google Scholar] [CrossRef]
  70. Lum, H.; Roebuck, K.A. Oxidant Stress and Endothelial Cell Dysfunction. Am. J. Physiol. Cell Physiol. 2001, 280, C719–C741. [Google Scholar] [CrossRef]
  71. Starke, R.M.; Chalouhi, N.; Ali, M.S.; Jabbour, P.M.; Tjoumakaris, S.I.; Gonzalez, L.F.; Rosenwasser, R.H.; Koch, W.J.; Dumont, A.S. The Role of Oxidative Stress in Cerebral Aneurysm Formation and Rupture. Curr. Neurovasc. Res. 2013, 10, 247–255. [Google Scholar] [CrossRef]
  72. Sadamasa, N.; Nozaki, K.; Hashimoto, N. Disruption of Gene for Inducible Nitric Oxide Synthase Reduces Progression of Cerebral Aneurysms. Stroke 2003, 34, 2980–2984. [Google Scholar] [CrossRef]
  73. Malek, A.M.; Hippelheuser, J.E.; Lauric, A. Vortex Formation and Associated Aneurysmogenic Transverse Rotational Shear Stress near the Apex of Wide-Angle Cerebral Bifurcations. J. Neurosurg. 2022, 136, 1726–1737. [Google Scholar] [CrossRef]
  74. Fang, J.; Sheng, R.; Qin, Z.-H. NADPH Oxidases in the Central Nervous System: Regional and Cellular Localization and the Possible Link to Brain Diseases. Antioxid. Redox Signal 2021, 35, 951–973. [Google Scholar] [CrossRef]
  75. Šćepanović, V.; Tasić, G.; Repac, N.; Nikolić, I.; Janićijević, A.; Todorović, D.; Stojanović, M.; Šćepanović, R.; Mitrović, D.; Šćepanović, T.; et al. The Role of Oxidative Stress as a Risk Factor for Rupture of Posterior Inferior Cerebellar Artery Aneurysms. Mol. Biol. Rep. 2018, 45, 2157–2165. [Google Scholar] [CrossRef]
  76. Jiang, W.-C.; Chen, C.-M.; Hamdin, C.D.; Orekhov, A.N.; Sobenin, I.A.; Layne, M.D.; Yet, S.-F. Therapeutic Potential of Heme Oxygenase-1 in Aneurysmal Diseases. Antioxidants 2020, 9, 1150. [Google Scholar] [CrossRef] [PubMed]
  77. Chrissobolis, S.; Faraci, F.M. The Role of Oxidative Stress and NADPH Oxidase in Cerebrovascular Disease. Trends Mol. Med. 2008, 14, 495–502. [Google Scholar] [CrossRef] [PubMed]
  78. Zhang, X.; Ma, L.; Liang, D.; Song, B.; Chen, J.; Huang, Y.; Xu, L.; Zhao, P.; Wu, W.; Zhang, N.; et al. Neurofilament Light Protein Predicts Disease Progression in Idiopathic REM Sleep Behavior Disorder. J. Park. Dis. 2023, 13, 485–499. [Google Scholar] [CrossRef]
  79. Xiong, W.; Mactaggart, J.; Knispel, R.; Worth, J.; Zhu, Z.; Li, Y.; Sun, Y.; Baxter, B.T.; Johanning, J. Inhibition of Reactive Oxygen Species Attenuates Aneurysm Formation in a Murine Model. Atherosclerosis 2009, 202, 128–134. [Google Scholar] [CrossRef] [PubMed]
  80. Sorce, S.; Krause, K.-H.; Jaquet, V. Targeting NOX Enzymes in the Central Nervous System: Therapeutic Opportunities. Cell. Mol. Life Sci. 2012, 69, 2387–2407. [Google Scholar] [CrossRef]
  81. Chen, H.; Yoshioka, H.; Kim, G.S.; Jung, J.E.; Okami, N.; Sakata, H.; Maier, C.M.; Narasimhan, P.; Goeders, C.E.; Chan, P.H. Oxidative Stress in Ischemic Brain Damage: Mechanisms of Cell Death and Potential Molecular Targets for Neuroprotection. Antioxid. Redox Signal 2011, 14, 1505–1517. [Google Scholar] [CrossRef]
  82. Ma, M.W.; Wang, J.; Zhang, Q.; Wang, R.; Dhandapani, K.M.; Vadlamudi, R.K.; Brann, D.W. NADPH Oxidase in Brain Injury and Neurodegenerative Disorders. Mol. Neurodegener. 2017, 12, 7. [Google Scholar] [CrossRef]
  83. Dang, D.N.P.; Kamio, Y.; Kawakatsu, T.; Makino, H.; Hokamura, K.; Imai, R.; Suzuki, Y.; Hiramatsu, H.; Zhitong, L.; Umemura, K.; et al. Protective Effect of Resveratrol Against Intracranial Aneurysm Rupture in Mice. J. Neurosci. Res. 2025, 103, e70059. [Google Scholar] [CrossRef]
  84. Jin, T.; An, Q.; Qin, X.; Qin, X.; Hu, Y.; Hu, J.; Zhou, B.; Leng, B. Resveratrol Inhibits Cerebral Aneurysms in Mice via Downregulating the NF-κB Pathway. Acta Biochim. Pol. 2022, 69, 613–618. [Google Scholar] [CrossRef] [PubMed]
  85. Meng, X.; Zhou, J.; Zhao, C.-N.; Gan, R.-Y.; Li, H.-B. Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review. Foods 2020, 9, 340. [Google Scholar] [CrossRef] [PubMed]
  86. Bekelis, K.; Kerley-Hamilton, J.S.; Teegarden, A.; Tomlinson, C.R.; Kuintzle, R.; Simmons, N.; Singer, R.J.; Roberts, D.W.; Kellis, M.; Hendrix, D.A. MicroRNA and Gene Expression Changes in Unruptured Human Cerebral Aneurysms. J. Neurosurg. 2016, 125, 1390–1399. [Google Scholar] [CrossRef] [PubMed]
  87. Wang, X.; Pavlov, V.; Gareev, I.; Xu, S. Identification of Key Genes and miRNA-mRNA Regulatory Networks Associated with Intracranial Aneurysm Progression by Integrative Bioinformatics Analysis. Curr. Med. Chem. 2025. ahead of print. [Google Scholar] [CrossRef]
  88. Wang, M.; Wang, Y.; Zhang, P.; Gu, C.; Zhao, X.; Gong, X.; Yang, X.; Pan, J.; Xi, Y. Neutrophil-like Cell Membrane-Coated Metal-Organic Frameworks for siRNA Delivery Targeting NOX4 to Alleviate Oxidative Stress in Acute Ischemic Injury. Acta Biomater. 2025, 196, 487–505. [Google Scholar] [CrossRef]
  89. Ogilvy, C.S. Unruptured Intracranial Aneurysms. N. Engl. J. Med. 2025, 392, 2357–2366. [Google Scholar] [CrossRef]
  90. Chen, S.; Hu, Z.; Zhao, M.; Sun, J.; Nie, S.; Gao, X.; Huang, Y. A Comprehensive Proteomic Analysis Reveals Novel Inflammatory Biomarkers in Intracranial Aneurysms. J. Proteom. 2025, 313, 105374. [Google Scholar] [CrossRef]
  91. Sharma, T.; Datta, K.K.; Kumar, M.; Dey, G.; Khan, A.A.; Mangalaparthi, K.K.; Saharan, P.; Chinnapparaj, S.; Aggarwal, A.; Singla, N.; et al. Intracranial Aneurysm Biomarker Candidates Identified by a Proteome-Wide Study. OMICS 2020, 24, 483–492. [Google Scholar] [CrossRef]
  92. Sahoo, P.; Kundu, M.; Begum, J. Artificial Intelligence in Cancer Diagnosis: A Game-Changer in Healthcare. Curr. Pharm. Biotechnol. 2025, 26, 1314–1330. [Google Scholar] [CrossRef]
  93. Hussain, S.; Barbarite, E.; Chaudhry, N.S.; Gupta, K.; Dellarole, A.; Peterson, E.C.; Elhammady, M.S. Search for Biomarkers of Intracranial Aneurysms: A Systematic Review. World Neurosurg. 2015, 84, 1473–1483. [Google Scholar] [CrossRef]
  94. de Ferronato, G.A.; Cerezetti, M.B.; Bridi, A.; Prado, C.M.; Dos Santos, G.; Bastos, N.M.; da Rosa, P.M.S.; Ferst, J.G.; da Silveira, J.C. MicroRNA Profiling Using a PCR-Based Method. Methods Mol. Biol. 2023, 2595, 159–170. [Google Scholar] [CrossRef]
  95. Deng, J.; Ning, K.; Liu, D.; Wu, D.; Wan, R.; Ge, J. MiR-140 Promotes the Progression of Intracranial Aneurysms by Targeting BCL2L2. Neuroreport 2023, 34, 38–45. [Google Scholar] [CrossRef]
  96. Zhong, Z.; Wu, J.; Yuan, K.; Song, Z.; Ma, Z.; Zhong, Y.; Fang, X.; Zhang, W. Upregulation of microRNA-205 Is a Potential Biomarker for Intracranial Aneurysms. Neuroreport 2019, 30, 812–816. [Google Scholar] [CrossRef] [PubMed]
  97. Li, P.; Zhang, Q.; Wu, X.; Yang, X.; Zhang, Y.; Li, Y.; Jiang, F. Circulating microRNAs Serve as Novel Biological Markers for Intracranial Aneurysms. J. Am. Heart Assoc. 2014, 3, e000972. [Google Scholar] [CrossRef]
  98. Yasuno, K.; Bilguvar, K.; Bijlenga, P.; Low, S.-K.; Krischek, B.; Auburger, G.; Simon, M.; Krex, D.; Arlier, Z.; Nayak, N.; et al. Genome-Wide Association Study of Intracranial Aneurysm Identifies Three New Risk Loci. Nat. Genet. 2010, 42, 420–425. [Google Scholar] [CrossRef]
  99. Yasuno, K.; Bakırcıoğlu, M.; Low, S.-K.; Bilgüvar, K.; Gaál, E.; Ruigrok, Y.M.; Niemelä, M.; Hata, A.; Bijlenga, P.; Kasuya, H.; et al. Common Variant near the Endothelin Receptor Type A (EDNRA) Gene Is Associated with Intracranial Aneurysm Risk. Proc. Natl. Acad. Sci. USA 2011, 108, 19707–19712. [Google Scholar] [CrossRef] [PubMed]
  100. Meeuwsen, J.A.L.; van’ t Hof, F.N.G.; van Rheenen, W.; Rinkel, G.J.E.; Veldink, J.H.; Ruigrok, Y.M. Circulating microRNAs in Patients with Intracranial Aneurysms. PLoS ONE 2017, 12, e0176558. [Google Scholar] [CrossRef]
  101. Kim, H.; Kim, M.; Im, S.-K.; Fang, S. Mouse Cre-LoxP System: General Principles to Determine Tissue-Specific Roles of Target Genes. Lab. Anim. Res. 2018, 34, 147–159. [Google Scholar] [CrossRef] [PubMed]
  102. Zanaty, M.; Roa, J.A.; Nakagawa, D.; Chalouhi, N.; Allan, L.; Al Kasab, S.; Limaye, K.; Ishii, D.; Samaniego, E.A.; Jabbour, P.; et al. Aspirin Associated with Decreased Rate of Intracranial Aneurysm Growth. J. Neurosurg. 2020, 133, 1478–1485. [Google Scholar] [CrossRef]
  103. Weng, J.-C.; Wang, J.; Li, H.; Jiao, Y.-M.; Fu, W.-L.; Huo, R.; Yan, Z.-H.; Xu, H.-Y.; Zhan, J.; Wang, S.; et al. Aspirin and Growth of Small Unruptured Intracranial Aneurysm: Results of a Prospective Cohort Study. Stroke 2020, 51, 3045–3054. [Google Scholar] [CrossRef] [PubMed]
  104. Parisi, S.; Ditto, M.C.; Ghellere, F.; Panaro, S.; Piccione, F.; Borrelli, R.; Fusaro, E. Update on Tocilizumab in Rheumatoid Arthritis: A Narrative Review. Front. Immunol. 2025, 16, 1470488. [Google Scholar] [CrossRef] [PubMed]
  105. Siegel, C.A.; Hur, C.; Korzenik, J.R.; Gazelle, G.S.; Sands, B.E. Risks and Benefits of Infliximab for the Treatment of Crohn’s Disease. Clin. Gastroenterol. Hepatol. 2006, 4, 1017–1024, quiz 976. [Google Scholar] [CrossRef]
  106. Tsai, T.-L.; Wei, J.C.-C.; Wu, Y.-T.; Ku, Y.-H.; Lu, K.-L.; Wang, Y.-H.; Chiou, J.-Y. The Association Between Usage of Colchicine and Pneumonia: A Nationwide, Population-Based Cohort Study. Front. Pharmacol. 2019, 10, 908. [Google Scholar] [CrossRef]
  107. Liu, J.; Khalil, R.A. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. Prog. Mol. Biol. Transl. Sci. 2017, 148, 355–420. [Google Scholar] [CrossRef]
  108. Hoh, B.L.; Ko, N.U.; Amin-Hanjani, S.; Chou, S.H.-Y.; Cruz-Flores, S.; Dangayach, N.S.; Derdeyn, C.P.; Du, R.; Hänggi, D.; Hetts, S.W.; et al. 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline from the American Heart Association/American Stroke Association. Stroke 2023, 54, e314–e370, Erratum in Stroke 2023, 54, e516. [Google Scholar] [CrossRef] [PubMed]
  109. Vossen, L.V.; Weiss, M.; Albanna, W.; Conzen-Dilger, C.; Schulze-Steinen, H.; Rossmann, T.; Schmidt, T.P.; Höllig, A.; Wiesmann, M.; Clusmann, H.; et al. Intra-Arterial Nimodipine for the Treatment of Refractory Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage. J. Neurointerv. Surg. 2024, 17, e31–e40. [Google Scholar] [CrossRef]
  110. Eskey, C.J.; Meyers, P.M.; Nguyen, T.N.; Ansari, S.A.; Jayaraman, M.; McDougall, C.G.; DeMarco, J.K.; Gray, W.A.; Hess, D.C.; Higashida, R.T.; et al. Indications for the Performance of Intracranial Endovascular Neurointerventional Procedures: A Scientific Statement From the American Heart Association. Circulation 2018, 137, e661–e689. [Google Scholar] [CrossRef]
  111. McAvoy, M.; Ratner, B.; Ferreira, M.J.; Levitt, M.R. Gene Therapy for Intracranial Aneurysms: Systemic Review. J. Neurointerv. Surg. 2025, 17, 859–863. [Google Scholar] [CrossRef]
  112. Laurent, D.; Lucke-Wold, B.; Dodd, W.S.; Martinez, M.; Chowdhury, M.A.B.; Hosaka, K.; Motwani, K.; Hoh, B. Combination Release of Chemokines from Coated Coils to Target Aneurysm Healing. J. Neurointerv. Surg. 2023, 15, 689–694. [Google Scholar] [CrossRef] [PubMed]
  113. Chen, P.R.; Frerichs, K.; Spetzler, R. Natural History and General Management of Unruptured Intracranial Aneurysms. Neurosurg. Focus 2004, 17, E1. [Google Scholar] [CrossRef] [PubMed]
Ijms 26 10053 g001
Figure 1. Inflammatory molecular pathways in intracranial aneurysm. Hemodynamic shear stress generates endothelial cell damage that generates damage-associated molecular patterns (DAMPs). DAMPs bind to TLR4 on endothelial cells and vascular smooth muscle cells (VSMCs), activating nuclear factor κB (NF-κB). Endothelial NF-κB activation leads to the secretion of inflammatory cell chemotaxis molecules, chemokine receptor ligand 1 (CXCL1), interleukin-8 (IL-8), and monocyte chemoattractant protein-1 (MCP-1), leading to neutrophil and macrophage infiltration in intracranial aneurysm cell walls. VSMC NF-κB activation shifts VSMC phenotype to remodel intracranial aneurysm cell walls.
Figure 1. Inflammatory molecular pathways in intracranial aneurysm. Hemodynamic shear stress generates endothelial cell damage that generates damage-associated molecular patterns (DAMPs). DAMPs bind to TLR4 on endothelial cells and vascular smooth muscle cells (VSMCs), activating nuclear factor κB (NF-κB). Endothelial NF-κB activation leads to the secretion of inflammatory cell chemotaxis molecules, chemokine receptor ligand 1 (CXCL1), interleukin-8 (IL-8), and monocyte chemoattractant protein-1 (MCP-1), leading to neutrophil and macrophage infiltration in intracranial aneurysm cell walls. VSMC NF-κB activation shifts VSMC phenotype to remodel intracranial aneurysm cell walls.
Ijms 26 10053 g001
Ijms 26 10053 g002
Figure 2. Extracellular matrix remodeling in intracranial aneurysm (IA) begins early, with matrix metalloproteinases (MMPs) balanced by tissue inhibitors of MMPs (TIMPs). In late IAs, the MMP-to-TIMP ratio increases, leading to wall distension and rupture.
Figure 2. Extracellular matrix remodeling in intracranial aneurysm (IA) begins early, with matrix metalloproteinases (MMPs) balanced by tissue inhibitors of MMPs (TIMPs). In late IAs, the MMP-to-TIMP ratio increases, leading to wall distension and rupture.
Ijms 26 10053 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Hutchinson, H.; Rezk, R.; Farag, M.; Hanna, A.; Lucke-Wold, B. Molecular Targets for Intracranial Aneurysm Treatment. Int. J. Mol. Sci. 2025, 26, 10053. https://doi.org/10.3390/ijms262010053

AMA Style

Hutchinson H, Rezk R, Farag M, Hanna A, Lucke-Wold B. Molecular Targets for Intracranial Aneurysm Treatment. International Journal of Molecular Sciences. 2025; 26(20):10053. https://doi.org/10.3390/ijms262010053

Chicago/Turabian Style

Hutchinson, Hunter, Rogina Rezk, Mariam Farag, Abanob Hanna, and Brandon Lucke-Wold. 2025. "Molecular Targets for Intracranial Aneurysm Treatment" International Journal of Molecular Sciences 26, no. 20: 10053. https://doi.org/10.3390/ijms262010053

APA Style

Hutchinson, H., Rezk, R., Farag, M., Hanna, A., & Lucke-Wold, B. (2025). Molecular Targets for Intracranial Aneurysm Treatment. International Journal of Molecular Sciences, 26(20), 10053. https://doi.org/10.3390/ijms262010053

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop